AgingResearch.NewsJoin free

Vandria

CompanySwitzerland

Vandria develops one asset, in phase 1 (VNA-318 in Alzheimer's disease). Mostly small molecule acting on autophagy; based in Switzerland.

1
Asset
Furthest stage
Phase 1
Raised
US$70.7m
0
Trials
0
Signals

Pipeline

1

  • VNA-318

    Brain-penetrant mitophagy inducer that restores mitochondrial function and reduces inflammation.

    Phase 1, Small molecule, Autophagy, Alzheimer's disease, Major depressive disorder

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants3
  • People12
  • Similar companies6

Intelligence